Copyright ©The Author(s) 2020.
World J Gastroenterol. Jun 7, 2020; 26(21): 2740-2757
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2740
Table 1 Proven and possible effects of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors in diabetes and metabolism-associated fatty liver disease before and after liver transplantation
Therapy effectNAFLDT2DMPTDMPost-LT liver disease
GLP-1RA provenImprovement in liver enzymes and intrahepatic triglycerides content[113-116,130,131]Improvement of glycemia; increase insulin secretion in a glucose-dependent manner; inhibit glucagon secretion; weight loosing effect; cardiovascular protection[103-106]Improvement of insulin and normalization of glucagon concentrations[150]None metabolized by liver, no dose adjustments needed[156]
Resistance against toxicity of IS drugs in vitro[154]
Weight loss during first weeks after LT[158]
Improvements in weight, body mass index, glycemic control, liver enzymes, hsCRP[117]
Prevention of steroid diabetes[155]
Improvement in liver histology[118-120]
Resolution of NASH[122,127-129]
GLP-1RA possibleReduction of hepatic steatosis; anti-inflammatory effect[107-112]Improvement of cardiovascular outcomes[103-106], GI side effects potentiating GI disturbances caused by IS drugs[157]
SGLT-2i provenReduction of liver enzymes[65,135-142]Improvement of glycemia; weight loosing effect; decrease in systolic and diastolic blood pressures; cardiovascular benefit[132-134]Reduction of weight and blood pressure[162]
Improved glycemia[163]
Reduction of body weight and body fat[143-147]
SGLT2i possibleReduction of oxydative stress and inflammation[143-147]Genitourinary infections[164]Reduction in fat mass and visceral adipose tissue[165]